中国临床药学杂志

参考文献

[1] HAANEN J B A G, CARBONNEL F, ROBERT C, et al.Management of toxicities from immunotherapy:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol, 2017, 28(suppl_4):iv119.

[2] MEHNERT J M, MONJAZEB A M, BEERTHUIJZEN J M T, et al. The challenge for development of valuable immuno-oncology biomarkers[J]. Clin Cancer Res, 2017, 23(17):4970.

[3] YAMAUCHI I, SAKANE Y, FUKUDA Y, et al. Clinical features of nivolumab-induced thyroiditis:a case series study[J]. Thyroid,2017, 27(7):894.

[4] SHALIT A, SARANTIS P, KOUSTAS E, et al. Predictive biomarkers for immune-related endocrinopathies following immune checkpoint inhibitors treatment[J]. Cancers, 2023, 15(2):375.

[5] KOTWAL A, GUSTAFSON M P, BORNSCHLEGL S, et al.Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations[J].Thyroid, 2020, 30(10):1440.

[6] KAVVOURA F K, AKAMIZU T, AWATA T, et al. Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and a u t o i m m u n e t h y r o i d d i s e a s e:a M e t a-a n a l y s i s[J]. J C l i n Endocrinol Metab, 2007, 92(8):3162.

[7] YASUDA Y, IWAMA S, SUGIYAMA D, et al. CD4+T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice[J]. Sci Transl Med, 2021, 13(593):eabb7495.

[8] MUIR C A, MENZIES A M, CLIFTON-BLIGH R, et al. Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer[J]. Thyroid, 2020, 30(10):1458.

[9] KURIMOTO C, INABA H, ARIYASU H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors[J]. Cancer Sci, 2020, 111(5):1468.

[10] LEE H J, LI C W, HAMMERSTAD S S, et al. Immunogenetics of autoimmune thyroid diseases:a comprehensive review[J]. J Autoimmun, 2015, 64:82.

[11] LEE D J, LEE H J Jr, FARMER J R, et al. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors[J]. Curr Cardiol Rep, 2021,23(8):98.

[12] POLLACK R, ASHASH A, CAHN A, et al. Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index[J]. J Clin Endocrinol Metab, 2020, 105(10):dgaa458.

[13]张勤.免疫检查点抑制剂相关性甲状腺功能障碍的临床特征及影响因素分析[D].南昌:南昌大学, 2022.

[14] ZHANG J J, LOU J. Risk factors for thyroid dysfunction in patients with advanced non-small-cell lung cancer treated with PD-1 antibody[J]. Evid Based Complement Alternat Med, 2022,2022:9086962.

[15] POLLACK R M, KAGAN M, LOTEM M, et al. Baseline TSH level is associated with risk of anti–PD-1–induced thyroid dysfunction[J]. Endocr Pract, 2019, 25(8):824.

[16]卢超银. PD-1/PD-L1抑制剂导致甲状腺功能异常的临床特征与机制研究[D].温州:温州医科大学, 2021.

[17] PATIN E, HASAN M, BERGSTEDT J, et al. Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors[J]. Nat Immunol, 2018, 19(3):302.

[18] PIASECKA B, DUFFY D, URRUTIA A, et al. Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges[J]. Proc Natl Acad Sci U S A, 2018, 115(3):488.

[19] D'AIELLO A, LIN J, GUCALP R, et al. Thyroid dysfunction in lung cancer patients treated with immune checkpoint inhibitors(ICIs):outcomes in a multiethnic urban cohort[J]. Cancers,2021, 13(6):1464.

[20] KIM W, CHO Y A, KIM D C, et al. Factors associated with thyroid-related adverse events in patients receiving PD-1 or PDL1 inhibitors using machine learning models[J]. Cancers, 2021,13(21):5465.

[21] KIMBARA S, FUJIWARA Y, IWAMA S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab[J]. Cancer Sci, 2018,109(11):3583.

[22] BRILLI L, DANIELLI R, CAMPANILE M, et al. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy[J]. J Endocrinol Invest,2021, 44(8):1719.

[23] LUONGO C, MORRA R, GAMBALE C, et al. Higher baseline T S H l e v e l s p r e d i c t e a r l y h y p o t h y r o i d i s m d u r i n g c a n c e r immunotherapy[J]. J Endocrinol Invest, 2021, 44(9):1927.

[24] IWAMA S, KOBAYASHI T, ARIMA H. Clinical characteristics,management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors[J]. Endocrinol Metab,2021, 36(2):312.

[25] ZHOU X, IWAMA S, KOBAYASHI T, et al. Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline[J]. J Clin Endocrinol Metab,2023, 108(10):e1056.

[26]王瑞莲,谭锦云,卢梓荣,等.鼻咽癌患者经调强放疗序贯抗PD-1免疫治疗后甲状腺功能减退的影响因素[J].实用医学杂志,2021, 37(16):2114.

[27]叶强.免疫检查点抑制剂相关甲状腺不良事件的回顾性研究[D].广州:广州医科大学, 2022.

[28] KOYAMA J, HORIIKE A, YOSHIZAWA T, et al. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer[J]. J Thorac Dis, 2019, 11(5):1919.

[29] LU D F, YAO J, YUAN G H, et al. Immune checkpoint inhibitorrelated new-onset thyroid dysfunction:a retrospective analysis u s i n g t h e U S F D A a d v e r s e e v e n t r e p o r t i n g s y s t e m[J].Oncologist, 2022, 27(2):e126.

[30] SBARDELLA E, TENUTA M, SIRGIOVANNI G, et al. Thyroid disorders in programmed death 1 inhibitor-treated patients:is previous therapy with tyrosine kinase inhibitors a predisposing factor?[J]. Clin Endocrinol, 2020, 92(3):258.

[31] TSUGAWA Y, JENA A B, ORAV E J, et al. Age and sex of surgeons and mortality of older surgical patients:observational study[J]. BMJ, 2018, 361:k1343.

[32]冯涵,崔抗,耿一萌,等.程序性死亡受体1抑制剂对恶性实体瘤患者甲状腺功能的影响[J].中华实用诊断与治疗杂志, 2022,36(4):362.

[33]宋嘉.免疫检查点抑制剂相关内分泌代谢疾病[J].天津医科大学学报, 2021, 27(4):427.

[34] YAMAZAKI H, IWASAKI H, YAMASHITA T, et al. Potential risk factors for nivolumab-induced thyroid dysfunction[J]. In Vivo,2017, 31(6):1225.

[35] KANJANAPAN Y, DAY D, BUTLER M O, et al. Delayed immunerelated adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials[J]. Eur J Cancer, 2019, 107:1.

[36]侯静文,马晓君.程序性死亡受体1抑制剂相关甲状腺功能异常的影响因素分析[J].肿瘤基础与临床, 2021, 34(3):257.

[37]谭锦云.鼻咽癌调强放疗和抗PD-1免疫治疗后甲状腺功能减退的预测模型研究[D].广州:广州医科大学, 2022.

[38] GANNICHIDA A, NAKAZAWA Y, KAGEYAMA A, et al.Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer[J].World J Clin Oncol, 2022, 13(7):641.

[39]刘雅娟,莫丽钦,张晓诺,等.免疫检查点抑制药相关甲状腺功能障碍的预测及疗效预后临床研究[J].中国临床药理学杂志,2022, 38(22):2668.

[40] ZHANG Q, JIAO X J, LAI X Y. Clinical characters and influence factors of immune checkpoint inhibitor-related thyroid dysfunction[J]. J Clin Endocrinol Metab, 2023, 108(11):2916.